OPNT - Opiant Aptar expand collaboration for the making of Unidose nasal spray for OPNT003

Opiant Pharmaceuticals (NASDAQ:OPNT) on Wednesday said it would expand its long-term collaboration with Aptar Pharma for the making of Aptar's nasal Unidose device to be used in the production of commercial supply of Opiant's opioid overdose treatment OPNT003. The agreement includes a €2M investment by OPNT in Aptar. The agreement also includes a commitment by Aptar to install and maintain equipment in support of increased future production of its Unidose device to meet the potential commercial demand for OPNT003. OPNT had already initiated a rolling submission of a new drug application to the U.S FDA for OPNT003. It intends to complete the application in H2 2022. OPNT stock earlier closed -5.2% at $12.14.

For further details see:

Opiant, Aptar expand collaboration for the making of Unidose nasal spray for OPNT003